Sugi Predict

Sugi Predict / Compounds / SCHEMBL599322

SCHEMBL599322

SCHEMBL599322

CON[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 2/20 0.57
▸ KMT2A Q03164 1/20 0.53
▸ MME P08473 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ PPARG P37231 1/20 0.51
▸ PPARA Q07869 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ ATM Q13315 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ GAA P10253 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ NAALAD2 Q9Y3Q0 1/20 0.50
▸ MMP2 P08253 1/20 0.50
▸ MMP9 P14780 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL599323 1.00 FPR2 (0.57) FPR2KMT2AMMEL3MBTL1PPARG
SCHEMBL27709327 0.88 ATM (0.61) L3MBTL1ATMALDH1A1GAATHRB
SCHEMBL10296148 0.88 ATM (0.61) L3MBTL1ATMALDH1A1GAATHRB
SCHEMBL12386795 0.86 MMP1 (0.50) FPR2PPARGPPARAATMALDH1A1
Hydrochloric Acid SCHEMBL5934809 0.86 ATM (0.60) L3MBTL1ATMALDH1A1GAATHRB
SCHEMBL476060 0.86 FOLH1 (0.56) KMT2AMMEL3MBTL1NAALAD2
SCHEMBL476061 0.86 FOLH1 (0.56) KMT2AMMEL3MBTL1NAALAD2
Hydrochloric Acid SCHEMBL5934813 0.86 ATM (0.60) L3MBTL1ATMALDH1A1GAATHRB
SCHEMBL12386816 0.86 MMP2 (0.58) FPR2KMT2AL3MBTL1PPARGPPARA
SCHEMBL9388989 0.85 MMP1 (0.53) FPR2ALDH1A1MMP2MMP9THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630588-B2 Bicyclic peptide ligands specific for CD137 BICYCLETX LIMITED (GB) 2026-05-19 — — US claimed
US-20250059236-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 BICYCLETX LIMITED (GB) 2025-02-20 — — US claimed
US-20190177370-A1 PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) 2019-06-13 — — US claimed
EP-0950046-B1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS NAEJA PHARMACEUTICAL INC (CA) 2002-04-10 — — EP claimed
US-6232305-B1 ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS NAEJA PHARMACEUTICAL INC. (CA) 2001-05-15 — — US claimed
CN-1089269-A Novel 5-amino-4-hydroxy caproic acid derivative as therapeutical agent CIBA GEIGY AG (CH) 1994-07-13 — — CN claimed
US-12630588-B2 Bicyclic peptide ligands specific for CD137 BICYCLETX LIMITED (GB) 2026-05-19 — — US disclosed
CN-115298194-B VIPR2 antagonistic peptide 一丸自然美健有限公司 2026-05-12 — — CN disclosed
US-20260124312-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 BICYCLETX LIMITED (GB) 2026-05-07 — — US disclosed
US-20260035408-A1 WKYMVm peptide analogues having six residues and uses thereof RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV (KR) 2026-02-05 — — US disclosed
US-12534498-B2 Compounds for use as apelin receptor antagonists CAMBRIDGE ENTERPRISE LIMITED (GB) 2026-01-27 — — US disclosed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 — — US disclosed
EP-3876973-B1 INTERLEUKIN 10 CONJUGATES AND USES THEREOF SYNTHORX INC (US) 2025-10-22 — — EP disclosed
WO-1998050420-A1 SERINE PROTEASE INHIBITORS AKZO NOBEL N.V. (NL) 1998-11-12 — — WO disclosed
EP-0846127-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY Novartis AG (CH) 1998-06-10 — — EP disclosed
WO-1997008193-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY NOVARTIS AG (CH) 1997-03-06 — — WO disclosed
WO-1997007131-A1 ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES NOVARTIS AG (CH) 1997-02-27 — — WO disclosed
CN-1112125-A Acyloxyhexanoic acid derivatives CIBA GEIGY AG (CH) 1995-11-22 — — CN disclosed
CN-1089269-A Novel 5-amino-4-hydroxy caproic acid derivative as therapeutical agent CIBA GEIGY AG (CH) 1994-07-13 — — CN disclosed
US-4455303-A Renin inhibitors THE GENERAL HOSPITAL CORPORATION (US) 1984-06-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630588-B2 Bicyclic peptide ligands specific for CD137 PTMS, IL36G, HLA-A FPR2 849/4885KMT2A 1335/4885MME 256/4885
US-12534498-B2 Compounds for use as apelin receptor antagonists APLNR, NPBWR1, AP3B1 FPR2 95/4885KMT2A 903/4885MME 78/4885
US-20190177370-A1 PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF MYOF, MSTN, VIP FPR2 3389/4885KMT2A 1586/4885MME 124/4885
US-20260124312-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 EPHA2, EPHB2, ERBB2 FPR2 955/4885KMT2A 1304/4885MME 1596/4885
US-20250059236-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 CD2BP2, CD40, SDC1 FPR2 239/4885KMT2A 4692/4885MME 696/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 FPR2 904/4885KMT2A 2849/4885MME 3554/4885
US-20260035408-A1 WKYMVm peptide analogues having six residues and uses thereof HNMT, LTK, FPR3 FPR2 4/4885KMT2A 1351/4885MME 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.